These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 14679916)

  • 1. [Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase].
    D'Ausilio A; Marconi S; Antonini A; Tamma F; Valzania F; Berto P
    Recenti Prog Med; 2003 Nov; 94(11):484-93. PubMed ID: 14679916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.
    Valldeoriola F; Puig-Junoy J; Puig-Peiró R;
    J Med Econ; 2013; 16(2):191-201. PubMed ID: 23035627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
    Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
    J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Device-Aided Therapies in Parkinson's Disease: A Structured Review.
    Smilowska K; van Wamelen DJ; Pietrzykowski T; Calvano A; Rodriguez-Blazquez C; Martinez-Martin P; Odin P; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(2):475-489. PubMed ID: 33386813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacoeconomic study of the treatment of advanced Parkinson's disease].
    Vivancos-Matellano F; Garcia-Ruiz AJ; Garcia-Agua Soler N
    Rev Neurol; 2016 Dec; 63(12):529-536. PubMed ID: 27897303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease.
    Iskedjian M; Einarson TR
    Pharmacoeconomics; 2003; 21(2):115-27. PubMed ID: 12515573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
    Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
    Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of direct costs in therapy of Parkinson disease].
    Keller S; Kessler T; Meuser T; Fogel W; Bremen D; Jost WH
    Nervenarzt; 2003 Dec; 74(12):1105-9. PubMed ID: 14647911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of apomorphine in Parkinson's disease.
    Stocchi F
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ; Obering C
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Apomorphine therapy versus deep rain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease].
    Meissner W; Trottenberg T; Klaffke S; Paul G; Kühn AA; Arnold G; Einhäupl KM; Kupsch A
    Nervenarzt; 2001 Dec; 72(12):924-7. PubMed ID: 11789436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease].
    Puig-Junoy J; Puig Peiró R
    Neurologia; 2009 May; 24(4):220-9. PubMed ID: 19603291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 19. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs.
    Charles PD; Padaliya BB; Newman WJ; Gill CE; Covington CD; Fang JY; So SA; Tramontana MG; Konrad PE; Davis TL
    Parkinsonism Relat Disord; 2004 Dec; 10(8):475-9. PubMed ID: 15542007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.